Taisho Pharmaceutical Buys Back Shanghai Dazhengli Health Care Shares
This article was originally published in PharmAsia News
Japanese firm Taisho Pharmaceutical, a majority stakeholder of Shanghai Dazhengli Health Care, has purchased the latter's 15 percent shares held by Guan Shen Yuan (Group) at RMB 14.7994 million. Taisho Pharmaceutical, the world's leading OTC manufacturer, set up Shanghai Dazhengli Health Care in 1997 to promote and sell its Libogen products in China. Shanghai Dazhengli can output more than 20 million bottles of Lipovitan D nutrient drink annually, with China being Taisho's best overseas market. Taisho has been trying to expand its production capacity and sales in the country, with major markets extending from Shanghai to the north, northeast and south of China. Analysts observe that the buy-back indicates Taisho's confidence in the market. (Click here for more - Chinese Language)
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.